CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

CSPC Pharmaceutical Starts Phase I Trial of SYS6057 RSV Vaccine in China

By Public Technologies
  • CSPC Pharmaceutical Group announced on November 2, 2026, the launch of a Phase I trial in China for RSV vaccine SYS6057.
  • The trial will assess safety and immune response in adults aged 18 or older; participant recruitment and screening are underway.
  • Chinese regulators cleared the clinical trial in July 2026; the study is randomized, blinded and placebo-controlled.
  • SYS6057 targets lower respiratory tract disease caused by RSV infection.
  • Preclinical results reported in the announcement showed protection against both RSV subtypes, strong neutralizing antibody activity and durable immune protection.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261102-12395193), on November 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.